Keio University · Medicine
Professor Takehiko Mori's research lab specializes in hematopoietic stem cell transplantation and immune-mediated disorders, with a focus on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects. The lab investigates the dual role of donor immune cells in causing tissue damage (GVHD) or eliminating residual leukemia cells (GVL), using murine models to dissect the immunological and hematopoietic consequences. They also explore pharmacokinetic optimization of immunosuppressive agents like tacrolimus to improve outcomes in allogeneic hematopoietic stem cell transplantation. Their work bridges basic immunology with clinical transplantation medicine to enhance patient survival and reduce complications.
Figures are computed from collected data and may differ slightly.
The influence of graft-versus-host (GVH) reaction on the host hematopoietic cells clinically manifests itself both as adverse reactions in transfusion-associated GVH disease (GVHD) and as a therapeutic graft-versus-leukemia (GVL) effect in either donor lymphocytes transfusion (DLT) or allogeneic bone marrow (BM) transplantation. We examined the effect of GVH reaction on the host hematopoiesis in the murine parent-into-F1 (P1 --> F1) model of GVHD. The systemic transfer of 5 x 10(7) of C57BL/6 (B
Only limited data are available regarding the relationship between blood concentration of tacrolimus and its efficacy in preventing acute graft-versus-host disease (aGVHD). We retrospectively evaluated the effects of the whole blood concentration of tacrolimus, which was measured by an automated microparticle enzyme immunoassay, early after allogeneic hematopoietic stem cell transplantation (HSCT) upon the development of aGVHD. Sixty patients, who underwent allogeneic HSCT from serologically hum
Open papers in the app to read, cite, and organize with AI.
